Search Medical Condition
Please enter condition
Please choose location

Sun City, Arizona Clinical Trials

A listing of Sun City, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (139) clinical trials

ITI-007 for the Treatment of Agitation in Patients With Dementia Including Alzheimer's Disease

This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.

Phase

0.0 miles

Learn More »

We invite boys and girls aged 6 to 17 who have a diagnosis of Tourette syndrome to see if they may qualify for the T-Force Gold Study. The primary purpose of this research study is to determine the safety, tolerability, and effectiveness of an investigational medication for Tourette syndrome.Visit TForceGold.com to learn ...

Phase

0.57 miles

Learn More »

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

The A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains who may be at risk for memory loss and cognitive decline due to Alzheimer's disease. The A4 study will test an anti-amyloid investigational drug in older individuals who do not ...

Phase

0.75 miles

Learn More »

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2 week Safety Follow Up Period. Final eligibility will be determined at the Baseline Visit. Eligible patients will be randomized to receive placebo or SYN120 100 mg once a day (QD).

Phase

0.75 miles

Learn More »

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

The drug being tested in this study is called pioglitazone. This study is designed to further evaluate the safety and effectiveness of pioglitazone on cognitive function in participants who have completed the AD-4833/TOMM40_301. This study will look at the effectiveness of pioglitazone on cognitive decline in high-risk participants who have ...

Phase

0.75 miles

Learn More »

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

The purpose of study is to test the effects of an experimental medication GED-0301 (mongersen) in patients who have active Crohn's disease. The study will test GED-0301 compared to placebo for 52 weeks. The study treatment is blinded which means that patients and the study doctor will not know which ...

Phase

0.75 miles

Learn More »

Observational Registry of H.P. Acthar Gel for Multiple Sclerosis Relapse

This observational study aims to characterize the patient population and describe multiple sclerosis exacerbation recovery, treatment patterns and safety outcomes in patients with multiple sclerosis experiencing exacerbations treated with H.P. Acthar® Gel (Acthar Gel) in standard practice in the United States.

Phase N/A

0.75 miles

Learn More »

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

This is a long-term active treatment study in patients with Crohn's disease (CD). Subjects who met the early escape criteria in Study GED-0301-CD-002, or subjects who completed Study GED-0301-002 or GED-0301-003, may be eligible for this study. Primary objective is to assess long-term safety of GED 0301. Additional efficacy and ...

Phase

0.75 miles

Learn More »

CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and ...

Phase

0.75 miles

Learn More »

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

This is a double-blind, randomized, placebo-controlled, parallel-arm study in subjects with DLB or PDD who have RBD. Subjects who meet the randomization criteria will be randomized 1:1 to receive Nelotanserin or placebo for 28 days during the double-blind period.

Phase

0.75 miles

Learn More »